Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis

Barbara A. Fivush, Glenn H. Bock, Philip C. Guzzetta, Jose R. Salcedo, Edward J. Ruley

Research output: Contribution to journalArticle


Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P < .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis.

Original languageEnglish (US)
Pages (from-to)120-123
Number of pages4
JournalAmerican Journal of Kidney Diseases
Issue number2
StatePublished - Jan 1 1985
Externally publishedYes



  • Hemodialysis
  • PTFE grafts
  • vancomycin

ASJC Scopus subject areas

  • Nephrology

Cite this